Creative Planning
SPRY icon

Creative Planning’s ARS Pharmaceuticals SPRY Stock Holding History

Creative Planning’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$195K Buy
24,321
+48
+0.2% +$413 ﹤0.01% 3884
2026
Q1 		$195K Sell
24,273
-1,055
-4% -$10.1K ﹤0.01% 3745
2025
Q4 		$295K Sell
25,328
-1,847
-7% -$18K ﹤0.01% 3248
2025
Q3 		$273K Sell
27,175
-10,429
-28% -$150K ﹤0.01% 3218
2025
Q2 		$656K Buy
37,604
+4,485
+14% +$64.7K ﹤0.01% 2227
2025
Q1 		$417K Buy
33,119
+2,913
+10% +$35K ﹤0.01% 2465
2024
Q4 		$319K Sell
30,206
-5,057
-14% -$70.8K ﹤0.01% 2611
2024
Q3 		$511K Buy
35,263
+2,307
+7% +$27.4K ﹤0.01% 2089
2024
Q2 		$280K Buy
32,956
+594
+2% +$5.27K ﹤0.01% 2409
2024
Q1 		$331K Buy
32,362
+1,161
+4% +$8.66K ﹤0.01% 2174
2023
Q4 		$171K Buy
31,201
+3,270
+12% +$14.3K ﹤0.01% 2478
2023
Q3 		$106K Buy
+27,931
New +$183K ﹤0.01% 2390

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Creative Planning's SPRY Position: Q2 2026 in Review

Creative Planning increased its ARS Pharmaceuticals (SPRY) stake by 0.2% in Q2 2026, buying an estimated $413 and bringing the position to 24,321 shares worth $195K. The position accounts for ﹤0.01% of the portfolio, ranked #3884.

Creative Planning first reported a position in SPRY in Q3 2023 and has held it in 12 quarters since. The position peaked at $656K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Creative Planning held 24,321 shares of ARS Pharmaceuticals worth $195K as of Q2 2026.
  • Creative Planning bought 48 ARS Pharmaceuticals shares in Q2 2026, an estimated $413.
  • ARS Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3884 holding.
  • Creative Planning first reported a position in ARS Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Creative Planning's ARS Pharmaceuticals position peaked at $656K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.